Checkpoint inhibitors in bladder and renal cancers: results and perspectives

被引：20
|
作者：
Aoun, Fouad [1 ]
Kourie, Hampig R. [2 ]
Sideris, Spyridon [2 ]
Roumeguere, Thierry [3 ]
van Velthoven, Roland [1 ]
Gil, Thierry
机构：
[1] Inst Jules Bordet, Dept Urol, B-1000 Brussels, Belgium
[2] Inst Jules Bordet, Dept Oncol, B-1000 Brussels, Belgium
[3] Erasme Univ Hosp, Dept Urol, B-1070 Brussels, Belgium
来源：
IMMUNOTHERAPY | 2015年 / 7卷 / 12期
关键词：
bladder cancer; checkpoint inhibitors; CTLA4; immunotherapy; PD1/PDL1; renal cell carcinoma; TRANSITIONAL CELL-CARCINOMA; CLINICAL ACTIVITY; INTERFERON-ALPHA; TUMOR-CELL; HLA-G; BLOCKADE; IMMUNOTHERAPY; SURVIVAL; ANTIBODY; NIVOLUMAB;
D O I：
10.2217/imt.15.91
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The field of immunotherapy in urinary malignancy is expanding in several directions and checkpoint inhibitors are leading the way. The aim of this report is to highlight the efficacy and safety profile of the two classes of molecules, anti-cytotoxic T-lymphocyte antigen-4 and anti-programmed death receptor-1/programmed death ligand type 1, that are under investigation and represent potential candidates to be used in the near future for the management of bladder and renal cell cancer. The preliminary results as well as the future perspectives of this novel immunotherapy are analyzed. Novel immune checkpoint targets are reviewed as well.
引用
收藏
页码：1259 / 1271
页数：13
相关论文
共 50 条
  • [1] Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research
    Gadducci, Angiolo
    Guerrieri, Maria Elena
    [J]. ANTICANCER RESEARCH, 2017, 37 (11) : 5955 - 5965
  • [2] Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives
    Roviello, Giandomenico
    Catalano, Martina
    Santi, Raffaella
    Palmieri, Valeria Emma
    Vannini, Gianmarco
    Galli, Ilaria Camilla
    Buttitta, Eleonora
    Villari, Donata
    Rossi, Virginia
    Nesi, Gabriella
    [J]. CANCERS, 2021, 13 (17)
  • [3] Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives
    Taieb, Julien
    Moehler, Markus
    Boku, Narikazu
    Ajani, Jaffer A.
    Ruiz, Eduardo Yanez
    Ryu, Min-Hee
    Guenther, Silke
    Chand, Vikram
    Bang, Yung-Jue
    [J]. CANCER TREATMENT REVIEWS, 2018, 66 : 104 - 113
  • [4] Immune checkpoint inhibitors in GI cancers
    Lin, Chia-Chi
    [J]. CANCER SCIENCE, 2018, 109 : 828 - 828
  • [5] Checkpoint Inhibitors for Advanced Bladder Cancer
    Messing, Edward M.
    [J]. BLADDER CANCER, 2016, 2 (04) : 473 - 474
  • [6] Checkpoint inhibitors in gastrointestinal cancers:Expectations and reality
    Hampig Raphael Kourie
    Samer Tabchi
    Marwan Ghosn
    [J]. World Journal of Gastroenterology, 2017, (17) : 3017 - 3021
  • [7] Update on immune checkpoint inhibitors in gynecological cancers
    Heong, Valerie
    Ngoi, Natalie
    Tan, David Shao Peng
    [J]. JOURNAL OF GYNECOLOGIC ONCOLOGY, 2017, 28 (02)
  • [8] Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancers
    Karim, Frederic
    Amin, Adina
    Liu, Marie
    Vishnuvardhan, Nivetha
    Amin, Saif
    Shabbir, Raffey
    Swed, Brandon
    Khan, Uqba
    [J]. CANCERS, 2023, 15 (16)
  • [9] Immune checkpoint inhibitors for refractory childhood cancers
    Widemann, Brigitte C.
    [J]. LANCET ONCOLOGY, 2020, 21 (01): : 14 - 15
  • [10] An Overview of Immune Checkpoint Inhibitors in Gynecologic Cancers
    Castellano, Tara
    Moore, Kathleen N.
    Holman, Laura L.
    [J]. CLINICAL THERAPEUTICS, 2018, 40 (03) : 372 - 388
12345